Anti-Leukemia Drug May Also Work Against Ovarian Cancer

An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

The findings extend the anti-cancer potential of an experimental monoclonal antibody called cirmtuzumab, developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, and colleagues. Cirmtuzumab is currently in a first-in-human phase 1 clinical trial to assess its safety and efficacy in treating CLL. … Read the full story from the UC San Diego Newsroom


Dr. Thomas Kipps

Dr. Thomas Kipps

Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, is professor of medicine in the Division of Hematology-Oncology and deputy director of research at the UC San Diego Moores Cancer Center.

Dr. Kipps directs the multi-institutional, National Institutes of Health (NIH)-sponsored CLL Research Consortium (CRC) and UC San Diego Blood Cancer Research Fund.

Developmental Protein Plays Role in Spread of Cancer

A protein used by embryo cells during early development, and recently found in many different types of cancer, apparently serves as a switch regulating the spread of cancer, known as metastasis, report researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center in the June 15, 2013 issue of the journal Cancer Research. … Read the full story from the UCSD Newsroom


Dr. Thomas Kipps

Dr. Thomas Kipps

Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, is principal investigator of the study reported in Cancer Research.

Kipps is professor of medicine in the Division of Hematology-Oncology and deputy director of research at the UCSD Moores Cancer Center.

All study coauthors are affiliated with the Department of Medicine and the Moores Cancer Center.

Citation for the published study: Cui B, Zhang S, Chen L, Yu J, Widhopf GF II, Fecteau J-F, Rassenti LZ, and Kipps TJ. Targeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis. doi: 10.1158/0008-5472.CAN-12-3832 Cancer Res June 15, 2013 73; 3649  |  Read the abstract